Assessment of urodynamic and detrusor contractility variables in patients with overactive bladder syndrome treated with botulinum toxin-A: is incomplete bladder emptying predictable?
- PMID: 18990156
- DOI: 10.1111/j.1464-410X.2008.08076.x
Assessment of urodynamic and detrusor contractility variables in patients with overactive bladder syndrome treated with botulinum toxin-A: is incomplete bladder emptying predictable?
Abstract
Objective: To assess whether incomplete bladder emptying and the need for clean intermittent self-catheterization (CISC) is predictable, by analysing urodynamic and detrusor contractility variables in patients treated with botulinum toxin-A (BTX-A) for refractory idiopathic detrusor overactivity (IDO).
Patients and methods: Sixty-seven patients (mean age 50.3) with IDO, from two centres, had bladder injections of 200 U BTX-A. Patients with difficulty in emptying their bladder and/or persistent overactive bladder symptoms, with postvoid residual volumes (PVR) of >150 mL after treatment were started on CISC. Urodynamics were conducted at baseline, 4 and 12-16 weeks after injection with BTX-A. Detrusor contractility was assessed using the projected isovolumetric pressure (PIP1) in women and bladder contractility index (BCI) in men.
Results: There were improvements in the mean maximum cystometric capacity, bladder compliance and maximum detrusor pressures during filling cystometry after BTX-A injections. The PVR was significantly increased at 4 but not at 12 weeks. Nineteen patients required CISC and when compared with those not needing CISC their pretreatment maximum flow rate (15 vs 22 mL/s, P = 0.003), PIP1 (43 vs 58, P = 0.02) and BCI (113 vs 180, P = 0.001) were lower. Receiver operator characteristic curve analysis suggested that a PIP1 of < or =50 in women (sensitivity 0.83; specificity 0.70; area under the curve 0.822) and BCI < or =120 (sensitivity 0.7; specificity 0.79; area 0.879) might predict the need for CISC.
Conclusion: The maximum flow rate, PIP1 and BCI were significantly lower in patients who required CISC after BTX-A treatment than in those who did not. A PIP1 of < or =50 in women and a BCI of < or =120 might be predictive of a need for CISC in this setting, and might help when counselling patients.
Similar articles
-
Urodynamic assessment of poor responders after botulinum toxin-A treatment for overactive bladder.Urology. 2008 Mar;71(3):455-9. doi: 10.1016/j.urology.2007.11.039. Urology. 2008. PMID: 18342186
-
Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson's disease and multiple system atrophy.J Urol. 2009 Oct;182(4):1453-7. doi: 10.1016/j.juro.2009.06.023. Epub 2009 Aug 15. J Urol. 2009. PMID: 19683298
-
Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra.Urology. 2005 Jan;65(1):37-41. doi: 10.1016/j.urology.2004.08.016. Urology. 2005. PMID: 15667859
-
Predictors of Poor Response and Adverse Events Following Botulinum Toxin A for Refractory Idiopathic Overactive Bladder: A Systematic Review.Eur Urol Focus. 2021 Nov;7(6):1448-1467. doi: 10.1016/j.euf.2020.06.013. Epub 2020 Jun 29. Eur Urol Focus. 2021. PMID: 32616412
-
Mechanisms of action of intravesical botulinum treatment in refractory detrusor overactivity.BJU Int. 2008 Jul 25;102 Suppl 1:11-6. doi: 10.1111/j.1464-410X.2008.07822.x. BJU Int. 2008. PMID: 18665973 Review.
Cited by
-
Evaluation of the effect of 100U of Onabotulinum toxin A on detrusor contractility in women with idiopathic OAB: A multicentre prospective study.Neurourol Urodyn. 2022 Jan;41(1):306-312. doi: 10.1002/nau.24820. Epub 2021 Oct 19. Neurourol Urodyn. 2022. PMID: 34664738 Free PMC article.
-
Efficacy of botulinum toxin type A 100 Units versus 200 units for treatment of refractory idiopathic overactive bladder.Int Braz J Urol. 2015 Nov-Dec;41(6):1132-40. doi: 10.1590/S1677-5538.IBJU.2014.0221. Int Braz J Urol. 2015. PMID: 26742971 Free PMC article. Clinical Trial.
-
Botulinum toxin-A for the treatment of overactive bladder: UK contributions.J Clin Urol. 2013 Mar;6(2):77-83. doi: 10.1177/2051415812473096. J Clin Urol. 2013. PMID: 26097709 Free PMC article.
-
Intravesical instillation of botulinum toxin A: an in vivo murine study and pilot clinical trial.Int Urol Nephrol. 2011 Jun;43(2):337-43. doi: 10.1007/s11255-010-9790-z. Epub 2010 Jun 20. Int Urol Nephrol. 2011. PMID: 20563845 Clinical Trial.
-
Intravesical botulinum toxin for lower urinary tract dysfunction.F1000 Med Rep. 2010 Jan 27;2:6. doi: 10.3410/M2-6. F1000 Med Rep. 2010. PMID: 20948833 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials